RingCentral (RNG) shares have gained nearly 19% over the past six months, driven by expanding AI initiatives, strong demand ...

Starting later this year, Ouro intends to start a phase 1 clinical trial of its own, eyeing the development of the drug for ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ('Aspira' or the 'Company') (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of ...

Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms.

Germany's biologics market, the largest in Europe, is expected to grow at a 3.8% CAGR from 2025 to 2035. AI is driving this growth by enhancing R&D, optimizing drug design, and identifying novel ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Ramos, previously Pfizer's senior vice president and global head of BioTherapeutics R&D, has been appointed to the board of ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...